A large percentage of patients demonstrated normalization of key biomarkers associated with metabolic disease at a randomly selected follow-up timepoint, including Hemoglobin A1c (47.5%), fasting glucose (49.6%), LP-IR (64.3%), and fasting insulin (39.5%). This evidence concerns the gene INS and Other metabolic disease.